Loading...
Market
Percentage of drug-resistant TB patients completing BPaLM regimen by end of 2024?
2
Resolution / Starting Odds
Less than 50% • 25%
50% to 70% • 25%
70% to 90% • 25%
More than 90% • 25%
Union Health Ministry of India's official reports
Story
India Approves BPaLM Regimen for Drug-Resistant TB
Sep 6, 2024, 11:51 AM
The Union Health Ministry of India has approved the introduction of a new, shorter, and more efficacious treatment regimen for drug-resistant tuberculosis (TB). The BPaLM regimen, which consists of a four-drug combination—Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin—has been proven to be safe and more effective. This novel treatment will be implemented under the National TB Elimination Program and is expected to benefit India's 75,000 drug-resistant TB patients.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No increase or decrease • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 50% • 25%
50% to 74% • 25%
75% to 80% • 25%
More than 80% • 25%